Payment overview · 2025
General Payments
$4,628.39
78 reported records · 23 companies
Healthcare provider profile · identity verified
Pablo E Perez, MD
Allopathic & Osteopathic Physicians|Internal Medicine · DALTON, GA · NPI 1942218086
Verified facts
What the public records show
CMS Open Payments records show Pablo E Perez, MD received $4,628.39 in general payments during 2025 across 78 reported records.
Novo Nordisk Inc accounted for 56.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 34 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Jardiance, Linzess, Mounjaro, Ozempic, Prolia, Rybelsus, Trintellix, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Linzess by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 399 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 246 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 246 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 187 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 377 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Rybelsus by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Xifaxan by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Gemtesa by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $2,602.78 | 56.2% | 9 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $277.99 | 6.0% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $253.90 | 5.5% | 9 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $188.30 | 4.1% | 3 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $184.79 | 4.0% | 8 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $173.36 | 3.8% | 6 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $169.73 | 3.7% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $161.55 | 3.5% | 10 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $141.98 | 3.1% | 6 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $97.08 | 2.1% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $55.41 | 1.2% | 3 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $51.04 | 1.1% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $48.40 | 1.1% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $34.27 | 0.7% | 2 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $25.77 | 0.6% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $25.68 | 0.6% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $22.96 | 0.5% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $22.74 | 0.5% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $22.51 | 0.5% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $18.28 | 0.4% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.85 | 0.4% | 1 | 2025 |
| Ascendis Pharma Endocrinology Inc | Unresolved — no canonical attribution shown | $16.65 | 0.4% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $15.37 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $2,485.00 | 1 |
| Food and Beverage | $2,143.39 | 77 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $277.99 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $188.30 | 3 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $184.79 | 8 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $169.73 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $152.73 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $151.61 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $116.76 | 5 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $97.08 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $95.54 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $85.38 | 7 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $74.17 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $70.45 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $68.25 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $55.41 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $55.12 | 2 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $51.04 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $48.40 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $47.63 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $43.03 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $32.40 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $32.26 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $32.26 | 2 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $25.77 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $25.68 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $22.96 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $22.51 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $20.63 | 4 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18.28 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $17.85 | 1 | 2025 |
Source payment records
|
|||||
| Yorvipath Normalized: yorvipath |
Drug | Ascendis Pharma Endocrinology Inc | $16.65 | 1 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $15.37 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $14.25 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $12.77 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $3.97 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 399 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 94 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 246 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 81 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 85 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 377 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 39 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 102 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
81 | 21 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
39 | 27 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
399 | 115 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
65 | 33 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
246 | 70 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
246 | 70 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
85 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
187 | 46 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
377 | 86 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
102 | 35 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
94 | 23 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1326 | 410 |
| Amlodipine Besylate | Amlodipine Besylate | 895 | 272 |
| Metformin Hcl | Metformin Hcl | 826 | 270 |
| Levothyroxine Sodium | Levothyroxine Sodium | 811 | 218 |
| Alendronate Sodium | Alendronate Sodium | 800 | 243 |
| Losartan Potassium | Losartan Potassium | 769 | 220 |
| Gabapentin | Gabapentin | 763 | 252 |
| Pantoprazole Sodium | Pantoprazole Sodium | 706 | 239 |
| Atorvastatin Calcium | Atorvastatin Calcium | 693 | 217 |
| Lisinopril | Lisinopril | 562 | 187 |
| Omeprazole | Omeprazole | 536 | 182 |
| Tamsulosin Hcl | Tamsulosin Hcl | 466 | 162 |
| Farxiga | Dapagliflozin Propanediol | 399 | 115 |
| Ozempic | Semaglutide | 377 | 86 |
| Fluticasone Propionate | Fluticasone Propionate | 367 | 187 |
| Duloxetine Hcl | Duloxetine Hcl | 351 | 121 |
| Montelukast Sodium | Montelukast Sodium | 332 | 121 |
| Tramadol Hcl | Tramadol Hcl | 255 | 96 |
| Jardiance | Empagliflozin | 246 | 70 |
| Metoprolol Tartrate | Metoprolol Tartrate | 240 | 73 |
| Mirtazapine | Mirtazapine | 231 | 87 |
| Tresiba Flextouch U-100 | Insulin Degludec | 210 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 208 | 63 |
| Tizanidine Hcl | Tizanidine Hcl | 207 | 110 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 205 | 67 |
| Furosemide | Furosemide | 191 | 60 |
| Famotidine | Famotidine | 188 | 68 |
| Trulicity | Dulaglutide | 187 | 46 |
| Sertraline Hcl | Sertraline Hcl | 177 | 65 |
| Carvedilol | Carvedilol | 174 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 173 | 64 |
| Doxazosin Mesylate | Doxazosin Mesylate | 172 | 58 |
| Ezetimibe | Ezetimibe | 170 | 49 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 166 | 67 |
| Escitalopram Oxalate | Escitalopram Oxalate | 163 | 65 |
| Vascepa | Icosapent Ethyl | 162 | 54 |
| Tresiba Flextouch U-200 | Insulin Degludec | 160 | 39 |
| Lovastatin | Lovastatin | 154 | 45 |
| Clopidogrel | Clopidogrel Bisulfate | 146 | 49 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 145 | 38 |
| Metformin Hcl Er | Metformin Hcl | 142 | 44 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 142 | 32 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 141 | 40 |
| Trazodone Hcl | Trazodone Hcl | 140 | 59 |
| Dutasteride | Dutasteride | 136 | 47 |
| Dicyclomine Hcl | Dicyclomine Hcl | 135 | 64 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 127 | 32 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 127 | 60 |
| Eliquis | Apixaban | 126 | 30 |
| Januvia | Sitagliptin Phosphate | 124 | 36 |
| Fenofibrate | Fenofibrate | 122 | 41 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 121 | 38 |
| Donepezil Hcl | Donepezil Hcl | 118 | 46 |
| Pregabalin | Pregabalin | 114 | 41 |
| Hydralazine Hcl | Hydralazine Hcl | 108 | 30 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 104 | 29 |
| Rybelsus | Semaglutide | 102 | 35 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 97 | 56 |
| Diclofenac Sodium | Diclofenac Sodium | 96 | 63 |
| Bupropion Hcl Sr | Bupropion Hcl | 95 | 40 |
| Gemtesa | Vibegron | 94 | 23 |
| Methylprednisolone | Methylprednisolone | 91 | 71 |
| Atenolol | Atenolol | 87 | 22 |
| Allopurinol | Allopurinol | 85 | 26 |
| Mounjaro | Tirzepatide | 85 | 20 |
| Potassium Chloride | Potassium Chloride | 84 | 27 |
| Meloxicam | Meloxicam | 83 | 43 |
| Linzess | Linaclotide | 81 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 81 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 77 | 24 |
| Paroxetine Hcl | Paroxetine Hcl | 75 | 26 |
| Topiramate | Topiramate | 73 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 72 | 22 |
| Fenofibrate | Fenofibrate Nanocrystallized | 70 | 21 |
| Ammonium Lactate | Ammonium Lactate | 65 | 39 |
| Symbicort | Budesonide/Formoterol Fumarate | 65 | 33 |
| Bupropion Xl | Bupropion Hcl | 63 | 24 |
| Pioglitazone Hcl | Pioglitazone Hcl | 62 | 18 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 61 | 16 |
| Fluconazole | Fluconazole | 61 | 37 |
| Azithromycin | Azithromycin | 60 | 52 |
| Ropinirole Hcl | Ropinirole Hcl | 58 | 20 |
| Humalog Kwikpen U-100 | Insulin Lispro | 57 | 18 |
| Cefdinir | Cefdinir | 56 | 51 |
| Finasteride | Finasteride | 55 | 19 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 54 | 16 |
| Droplet Pen Needle | Pen Needle, Diabetic | 50 | 27 |
| Fluoxetine Hcl | Fluoxetine Hcl | 50 | 15 |
| Valsartan | Valsartan | 50 | 17 |
| Spironolactone | Spironolactone | 46 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 45 | 12 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 45 | 16 |
| Ondansetron Odt | Ondansetron | 40 | 30 |
| Novolog Flexpen | Insulin Aspart | 39 | 19 |
| Prolia | Denosumab | 39 | 27 |
| Terbinafine Hcl | Terbinafine Hcl | 39 | 23 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 38 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 38 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 38 | 16 |
| Breo Ellipta | Fluticasone/Vilanterol | 37 | 14 |
| Azelastine Hcl | Azelastine Hcl | 36 | 20 |
| Ketoconazole | Ketoconazole | 36 | 21 |
| Lidocaine | Lidocaine | 36 | 25 |
| Tradjenta | Linagliptin | 36 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 36 | 19 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 35 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 34 | 13 |
| Cephalexin | Cephalexin | 33 | 30 |
| Hydrocortisone | Hydrocortisone | 33 | 21 |
| Ondansetron Hcl | Ondansetron Hcl | 33 | 26 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 33 | 18 |
| Clonazepam | Clonazepam | 32 | 21 |
| Varenicline Tartrate | Varenicline Tartrate | 32 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 30 |
| Clonidine Hcl | Clonidine Hcl | 30 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 30 | suppressed |
| Nifedipine Er | Nifedipine | 30 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 29 | 27 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 29 | suppressed |
| Levetiracetam | Levetiracetam | 28 | suppressed |
| Celecoxib | Celecoxib | 27 | 17 |
| Paxlovid | Nirmatrelvir/Ritonavir | 26 | 25 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 25 | suppressed |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 25 | 16 |
| Bupropion Hcl | Bupropion Hcl | 24 | 12 |
| Dapagliflozin | Dapagliflozin Propanediol | 24 | 24 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Prednisone | Prednisone | 23 | 13 |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | 19 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 22 | 12 |
| Spiriva Respimat | Tiotropium Bromide | 22 | suppressed |
| Xifaxan | Rifaximin | 22 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 21 | suppressed |
| Colchicine | Colchicine | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Alprazolam | Alprazolam | 20 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | 19 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Nabumetone | Nabumetone | 20 | 18 |
| Lactulose | Lactulose | 19 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 19 | suppressed |
| Levofloxacin | Levofloxacin | 19 | 19 |
| Methotrexate | Methotrexate Sodium | 19 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | 13 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 16 | suppressed |
| Nystatin | Nystatin | 16 | 12 |
| Acamprosate Calcium | Acamprosate Calcium | 15 | suppressed |
| Brilinta | Ticagrelor | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 15 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 15 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Mupirocin | Mupirocin | 14 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 14 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Ofloxacin | Ofloxacin | 13 | 11 |
| Trintellix | Vortioxetine Hydrobromide | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 11 | suppressed |
| Amoxicillin | Amoxicillin | 11 | 11 |
| Icosapent Ethyl | Icosapent Ethyl | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 11 | suppressed |
| Simvastatin | Simvastatin | 11 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,628.39 · 78 records | Novo Nordisk Inc | ACCRUFER, AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, CREON, Dexcom G6 Transmitter, EVENITY, FARXIGA, GEMTESA, GVOKE HYPOPEN, General - Therapies, JARDIANCE, Kerendia, LINZESS, MOUNJARO, OTEZLA, Ozempic, PROLIA, QULIPTA, REPATHA, REXULTI, Rybelsus, TRINTELLIX, Tymlos, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, Wegovy, XIFAXAN, Yorvipath, ZEPBOUND, ZORYVE | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error